Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine

OBJECTIVE: Rimegepant is an orally administered small‐molecule calcitonin gene‐related peptide (CGRP) receptor antagonist, with demonstrated efficacy in the acute treatment of migraine. Recent estimates from a single‐arm trial (BHV3000‐201) have also shown evidence of long‐term preventive effects in...

Descripción completa

Detalles Bibliográficos
Autores principales: Popoff, Evan, Johnston, Karissa, Croop, Robert, Thiry, Alexandra, Harris, Linda, Powell, Lauren, Coric, Vladimir, L’Italien, Gilbert, Moren, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361942/
https://www.ncbi.nlm.nih.gov/pubmed/34021585
http://dx.doi.org/10.1111/head.14128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361942/
https://www.ncbi.nlm.nih.gov/pubmed/34021585
http://dx.doi.org/10.1111/head.14128

Ejemplares similares